A PROSPECTIVE PRESCRIPTION COST ANALYSIS OF ASTHMA MEDICATION

Author(s)

Khan AH1, Aftab RA1, Sulaiman SA1, Ali I2
1Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2General Hospital Penang, Pulau Pinang, Malaysia

OBJECTIVES: To review patient’s prescriptions and calculate direct cost for the treatment and management of asthma METHODS: A prospective cross-sectional detailed review of 180 prescriptions written by 6 doctors was conducted at respiratory department of hospital pulau pinang, Malaysia. Medication price was confirmed from the hospital formulary. Interview with the key personals were conducted to identify activities of each service provided to asthma patients. This was followed by determination of time taken to complete each activity using stopwatch. The duration was captured 15 times for each for three alternate days and summarized as the mean time (minutes) for each activity. The cost of each employee per single activity was obtained by multiplying the mean time (minute) spent by that employee doing a specific activity by his/her salary per minute RESULTS: A total of 6 different classes of medications were prescribed to 180 asthma patients. β agonist was the most prescribed class of asthma medication that included Salbutamol 72 (39.8) and albuterol 20 (11) followed by Corticosteroids that included budisonide 59 (32.8%), prednisolone 16 (8.8%) and fluticasone 11 (6.1%). Fifty one (28.3%) units of budisonide/formoterol combination medication were prescribed followed by fluticasone/salmeterol 40 (22.2%). A total of RM 10610.79(USD) medication were prescribed to 180 asthma patients with average cost of RM 59.08 per patient.  The combination medication of budisonide/formoterol RM.5253 (USD) made the majority of total cost of asthma medication. Spirometry was performed for all 180 patients at every hospital visit that costed RM 5400.00. The cost of services provided by doctors and nursing staff for 180 asthma patients for single visit was RM 1198.8 and RM 331.2 respectively CONCLUSIONS: Combination medication adds a substantial cost to over all asthma cost. Careful selection of asthma pharmacotherapy can greatly reduce medication cost without compromising on treatment outcomes

Conference/Value in Health Info

2015-09, ISPOR Latin America 2015, Santiago, Chile

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PRS11

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×